IDL Diagnostics AB (publ) (STO:IDLDX)

IDL Diagnostics AB Revenue

IDL Diagnostics AB had revenue of 14.56M SEK in the quarter ending June 30, 2026, with 43.51% growth. This brings the company's total for the last twelve months to 58.95M, up 7.55% year-over-year. In the year 2025, IDL Diagnostics AB had annual revenue of 53.11M, down -7.54%. That makes IDL Diagnostics AB the 39,384th largest company in the world by revenue and 547th in Sweden.

• Revenue (ttm): 58.95M
• Revenue Growth: +7.55%
• P/S Ratio: 1.39
• Revenue / Employee: 2.36M
• Employees: 25
• Market Cap: 81.78M

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Bacteriology 29.58M 55.7%
• Oncology 23.46M 44.2%
• Other Segments 76.00K 0.1%

By Geography

Chart

• Asia 29.48M 55.5%
• Europe 23.21M 43.7%
• Mea 171.00K 0.3%
• Americas 139.00K 0.3%
• Africa 113.00K 0.2%

Fiscal year ended Dec 31, 2025 See the full IDL Diagnostics AB breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	53.11M	-4.33M	-7.54%
Dec 31, 2024	57.44M	14.40M	33.45%
Dec 31, 2023	43.04M	6.05M	16.37%
Dec 31, 2022	36.99M	24.99M	208.32%
Dec 31, 2021	12.00M	11.91M	14,180.95%

Data Source: S&P Global Market Intelligence Last updated: Aug 20, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 15, 2026

Data Sources Report a data error